GLP1 Receptor Agonist

PreclinicalSmall molecule

Sanofi

GLP1 Receptor Agonist is one of 75 small molecule programs targeting Weight loss. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Weight LossActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Weight LossPreclinical

Active, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

169 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Jesduvroq

GGlaxo Dba Glaxosmithkline

Phase 3

11 2

Uloric

Takeda

Preclinical

2 3

Sovaldi

Gilead

Preclinical

1 4

Glucotrol

Pfizer

Preclinical

1 5

Vemlidy

Gilead

Preclinical

1 6

Lorelco

Sanofi

Preclinical

1 7

Activase

Flomax

Januvia

ZZydus Therapeutics Inc.

Preclinical

1 10

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Not yet recruiting

Weight Loss

NCT07175805

Clinical

Trials by Indication[1]

Weight loss1 trial

Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy

Not yet recruiting·HHartford HealthCare··NCT07175805·200 enrolled

Chronic Kidney Disease1 trial

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

Completed·WWeill Medical College of Cornell University··NCT03921242·4,888 enrolled

GLP-11 trial

Impact of GLP-1 Receptor Agonists on Patients With IPMN

Not yet recruiting·HHôpital Fribourgeois··NCT07014709·30 enrolled

Diabetes1 trial

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

Completed·UUniversity of California, San Francisco·N/A·NCT02846233·22 enrolled

Type 2 Diabetes Mellitus1 trial

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Completed· Sanofi logo

Sanofi·Phase 4·NCT02954692·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GLP1 Receptor Agonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLP1 Receptor Agonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLP1 Receptor Agonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Sanofi

GLP1 Receptor Agonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Weight loss1 trial

Chronic Kidney Disease1 trial

GLP-11 trial

Diabetes1 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News